FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption

Diana Jung, Takeshi Inagaki, Robert D. Gerard, Paul A. Dawson, Steven A. Kliewer, David J. Mangelsdorf, Antonio Moschetta

Research output: Contribution to journalArticle

Abstract

Bile acid malabsorption, which in patients leads to excessive fecal bile acid excretion and diarrhea, is characterized by a vicious cycle in which the feedback regulation of bile acid synthesis is interrupted, resulting in additional bile acid production. Feedback regulation of bile acid synthesis is under the control of an endocrine pathway wherein activation of the nuclear bile acid receptor, farnesoid X receptor (FXR), induces enteric expression of the hormone, fibroblast growth factor 15 (FGF15). In liver, FGF15 acts together with FXR-mediated expression of small heterodimer partner to repress bile acid synthesis. Here, we show that the FXR-FGF15 pathway is disrupted in mice lacking apical ileal bile acid transporter, a model of bile acid malabsorption. Treatment of Asbt-/- mice with either a synthetic FXR agonist or FGF15 downregulates hepatic cholesterol 7α-hydroxylase mRNA levels, decreases bile acid pool size, and reduces fecal bile acid excretion. jlr These findings suggest that FXR agonists or FGF15 could be used therapeutically to interrupt the cycle of excessive bile acid production in patients with bile acid malabsorption.

Original languageEnglish
Pages (from-to)2693-2700
Number of pages8
JournalJournal of Lipid Research
Volume48
Issue number12
DOIs
Publication statusPublished - Dec 2007

Fingerprint

Fibroblast Growth Factor Receptors
Fibroblast Growth Factors
Bile Acids and Salts
Cholesterol 7-alpha-Hydroxylase
Gastrointestinal Hormones
Feedback
Liver
Diarrhea
Down-Regulation

Keywords

  • Bile acid metabolism
  • Farnesoid X receptor
  • Fibroblast growth factor 15
  • Nuclear receptors
  • Transporters

ASJC Scopus subject areas

  • Endocrinology

Cite this

Jung, D., Inagaki, T., Gerard, R. D., Dawson, P. A., Kliewer, S. A., Mangelsdorf, D. J., & Moschetta, A. (2007). FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. Journal of Lipid Research, 48(12), 2693-2700. https://doi.org/10.1194/jlr.M700351-JLR200

FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. / Jung, Diana; Inagaki, Takeshi; Gerard, Robert D.; Dawson, Paul A.; Kliewer, Steven A.; Mangelsdorf, David J.; Moschetta, Antonio.

In: Journal of Lipid Research, Vol. 48, No. 12, 12.2007, p. 2693-2700.

Research output: Contribution to journalArticle

Jung, D, Inagaki, T, Gerard, RD, Dawson, PA, Kliewer, SA, Mangelsdorf, DJ & Moschetta, A 2007, 'FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption', Journal of Lipid Research, vol. 48, no. 12, pp. 2693-2700. https://doi.org/10.1194/jlr.M700351-JLR200
Jung, Diana ; Inagaki, Takeshi ; Gerard, Robert D. ; Dawson, Paul A. ; Kliewer, Steven A. ; Mangelsdorf, David J. ; Moschetta, Antonio. / FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption. In: Journal of Lipid Research. 2007 ; Vol. 48, No. 12. pp. 2693-2700.
@article{d49eed25afad4c9d8e380bd73d25a218,
title = "FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption",
abstract = "Bile acid malabsorption, which in patients leads to excessive fecal bile acid excretion and diarrhea, is characterized by a vicious cycle in which the feedback regulation of bile acid synthesis is interrupted, resulting in additional bile acid production. Feedback regulation of bile acid synthesis is under the control of an endocrine pathway wherein activation of the nuclear bile acid receptor, farnesoid X receptor (FXR), induces enteric expression of the hormone, fibroblast growth factor 15 (FGF15). In liver, FGF15 acts together with FXR-mediated expression of small heterodimer partner to repress bile acid synthesis. Here, we show that the FXR-FGF15 pathway is disrupted in mice lacking apical ileal bile acid transporter, a model of bile acid malabsorption. Treatment of Asbt-/- mice with either a synthetic FXR agonist or FGF15 downregulates hepatic cholesterol 7α-hydroxylase mRNA levels, decreases bile acid pool size, and reduces fecal bile acid excretion. jlr These findings suggest that FXR agonists or FGF15 could be used therapeutically to interrupt the cycle of excessive bile acid production in patients with bile acid malabsorption.",
keywords = "Bile acid metabolism, Farnesoid X receptor, Fibroblast growth factor 15, Nuclear receptors, Transporters",
author = "Diana Jung and Takeshi Inagaki and Gerard, {Robert D.} and Dawson, {Paul A.} and Kliewer, {Steven A.} and Mangelsdorf, {David J.} and Antonio Moschetta",
year = "2007",
month = "12",
doi = "10.1194/jlr.M700351-JLR200",
language = "English",
volume = "48",
pages = "2693--2700",
journal = "Journal of Lipid Research",
issn = "0022-2275",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "12",

}

TY - JOUR

T1 - FXR agonists and FGF15 reduce fecal bile acid excretion in a mouse model of bile acid malabsorption

AU - Jung, Diana

AU - Inagaki, Takeshi

AU - Gerard, Robert D.

AU - Dawson, Paul A.

AU - Kliewer, Steven A.

AU - Mangelsdorf, David J.

AU - Moschetta, Antonio

PY - 2007/12

Y1 - 2007/12

N2 - Bile acid malabsorption, which in patients leads to excessive fecal bile acid excretion and diarrhea, is characterized by a vicious cycle in which the feedback regulation of bile acid synthesis is interrupted, resulting in additional bile acid production. Feedback regulation of bile acid synthesis is under the control of an endocrine pathway wherein activation of the nuclear bile acid receptor, farnesoid X receptor (FXR), induces enteric expression of the hormone, fibroblast growth factor 15 (FGF15). In liver, FGF15 acts together with FXR-mediated expression of small heterodimer partner to repress bile acid synthesis. Here, we show that the FXR-FGF15 pathway is disrupted in mice lacking apical ileal bile acid transporter, a model of bile acid malabsorption. Treatment of Asbt-/- mice with either a synthetic FXR agonist or FGF15 downregulates hepatic cholesterol 7α-hydroxylase mRNA levels, decreases bile acid pool size, and reduces fecal bile acid excretion. jlr These findings suggest that FXR agonists or FGF15 could be used therapeutically to interrupt the cycle of excessive bile acid production in patients with bile acid malabsorption.

AB - Bile acid malabsorption, which in patients leads to excessive fecal bile acid excretion and diarrhea, is characterized by a vicious cycle in which the feedback regulation of bile acid synthesis is interrupted, resulting in additional bile acid production. Feedback regulation of bile acid synthesis is under the control of an endocrine pathway wherein activation of the nuclear bile acid receptor, farnesoid X receptor (FXR), induces enteric expression of the hormone, fibroblast growth factor 15 (FGF15). In liver, FGF15 acts together with FXR-mediated expression of small heterodimer partner to repress bile acid synthesis. Here, we show that the FXR-FGF15 pathway is disrupted in mice lacking apical ileal bile acid transporter, a model of bile acid malabsorption. Treatment of Asbt-/- mice with either a synthetic FXR agonist or FGF15 downregulates hepatic cholesterol 7α-hydroxylase mRNA levels, decreases bile acid pool size, and reduces fecal bile acid excretion. jlr These findings suggest that FXR agonists or FGF15 could be used therapeutically to interrupt the cycle of excessive bile acid production in patients with bile acid malabsorption.

KW - Bile acid metabolism

KW - Farnesoid X receptor

KW - Fibroblast growth factor 15

KW - Nuclear receptors

KW - Transporters

UR - http://www.scopus.com/inward/record.url?scp=37249011815&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37249011815&partnerID=8YFLogxK

U2 - 10.1194/jlr.M700351-JLR200

DO - 10.1194/jlr.M700351-JLR200

M3 - Article

C2 - 17823457

AN - SCOPUS:37249011815

VL - 48

SP - 2693

EP - 2700

JO - Journal of Lipid Research

JF - Journal of Lipid Research

SN - 0022-2275

IS - 12

ER -